Andrew G Gianoukakis
Overview
Explore the profile of Andrew G Gianoukakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
French J, Haugen B, Worden F, Bowles D, Gianoukakis A, Konda B, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3757-3767.
PMID: 38922338
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the...
2.
Gianoukakis A, Choe J, Bowles D, Brose M, Wirth L, Owonikoko T, et al.
Eur Thyroid J
. 2023 Dec;
13(1).
PMID: 38096102
Background: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes...
3.
Taylor M, Leboulleux S, Panaseykin Y, Konda B, De La Fouchardiere C, Hughes B, et al.
Cancer Med
. 2022 Dec;
12(4):4332-4342.
PMID: 36464853
Background: In the phase 2 double-blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine-refractory differentiated...
4.
Ho A, Dedecjus M, Wirth L, Tuttle R, Inabnet 3rd W, Tennvall J, et al.
J Clin Oncol
. 2022 Feb;
40(17):1870-1878.
PMID: 35192411
Purpose: Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC)...
5.
Gouda M, Ong E, Huang H, McPhaul L, Yoon S, Janku F, et al.
Endocrine
. 2022 Feb;
76(2):491-494.
PMID: 35152349
No abstract available.
6.
Brose M, Panaseykin Y, Konda B, De La Fouchardiere C, Hughes B, Gianoukakis A, et al.
J Clin Endocrinol Metab
. 2021 Oct;
107(3):776-787.
PMID: 34664662
Background: Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a...
7.
Gianoukakis A, Gupta S, Tran T, Richards P, Yehuda M, Tomassetti S
Am J Blood Res
. 2021 Jul;
11(3):238-247.
PMID: 34322286
Background: Graves' disease (GD) has been associated with iron deficiency anemia (IDA). Atrophic gastritis leads to IDA and has been associated with autoimmune thyroid disease. This study prospectively determined the...
8.
Yin N, Sherman S, Pak Y, Litofsky D, Gianoukakis A
Thyroid
. 2020 Jun;
30(11):1686-1687.
PMID: 32484055
No abstract available.
9.
Yin N, Sherman S, Pak Y, Litofsky D, Gianoukakis A
Thyroid
. 2020 Apr;
30(10):1490-1495.
PMID: 32228151
The prevalence and clinical significance of detection of anti-thyroglobulin antibodies (TgAbs) during the follow-up of patients with differentiated thyroid cancer (DTC) is unknown. We utilized the National Thyroid Cancer Treatment...
10.
McCartney C, Gianoukakis A, Gopalakrishnan G, McGill J, Roach P, Siraj E, et al.
J Grad Med Educ
. 2019 Aug;
11(4):378-381.
PMID: 31440329
No abstract available.